How do novel molecular genetic markers influence treatment decisions in acute myeloid leukemia?

Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program

Volumn 2012, Issue , 2012, Pages 28-34

  Patel, Jay P ^a   Levine, Ross L ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ASXL1 PROTEIN, HUMAN; CARRIER PROTEIN; DAUNORUBICIN; DNA (CYTOSINE 5) METHYLTRANSFERASE; DNA BINDING PROTEIN; DNA METHYLTRANSFERASE 3A; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 2, HUMAN; ONCOPROTEIN; PHF6 PROTEIN, HUMAN; REPRESSOR PROTEIN; TET2 PROTEIN, HUMAN;

ACUTE GRANULOCYTIC LEUKEMIA; ALLELE; ANIMAL; BIOLOGICAL MODEL; GENETIC ASSOCIATION; GENETIC MARKER; GENETICS; GENOMICS; HEMATOLOGY; HUMAN; METHODOLOGY; MOUSE; MUTATION; NUCLEOTIDE SEQUENCE; ONCOLOGY; REVIEW;

ALLELES; ANIMALS; CARRIER PROTEINS; DAUNORUBICIN; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; GENETIC MARKERS; GENOME-WIDE ASSOCIATION STUDY; GENOMICS; HEMATOLOGY; HUMANS; ISOCITRATE DEHYDROGENASE; LEUKEMIA, MYELOID, ACUTE; MEDICAL ONCOLOGY; MICE; MODELS, GENETIC; MUTATION; PROTO-ONCOGENE PROTEINS; REPRESSOR PROTEINS;

EID: 84879352656     PISSN: None     EISSN: 15204383     Source Type: Journal    
DOI: 10.1182/asheducation.v2012.1.28.3797923     Document Type: Review

References (0)